Introduction {#Sec1}
============

The chemokine receptor CXCR4 and its endogenous ligand CXCL12 are expressed constitutively in the central nervous system (CNS) during development and adulthood and play important roles in physiology and pathology (Li and Ransohoff [@CR17]). The CXCL12/CXCR4 axis has been implicated in important neuronal functions, such as modulation of neurotransmission, differentiation, and survival (Guyon and Nahon [@CR8]; Li and Ransohoff [@CR17]). Stimulation of CXCR4 by its natural ligand CXCL12 activates different signaling pathways in neurons (Li and Ransohoff [@CR17]). Previous studies from our group have shown that CXCR4 also controls specific cell cycle regulators such as p53 and the cdk-Rb-E2F pathway in postmitotic neurons (Khan et al. [@CR13]; Shimizu et al. [@CR32]; Khan et al. [@CR14]). These proteins may be involved in transcriptional regulation of specific sets of genes that affect the survival of postmitotic neurons independently of their role in cell cycle (Becker and Bonni [@CR4]). In line with this, our findings indicate that CXCR4 positively regulates Rb and this controls the expression of E2F1 pro-apoptotic targets in neurons, thus resulting in neuroprotection (Khan et al. [@CR11]; Shimizu et al. [@CR32]; Khan et al. [@CR14]). Interestingly, non-physiological ligands of CXCR4 that induce abnormal stimulation of CXCR4, such as the HIV-1 envelope protein gp120~IIIB~, are unable to stimulate Rb function and induce neurotoxicity via E2F-dependent pathways (Shimizu et al. [@CR32]; Bachis et al. [@CR2]). This further supports the role of Rb in neuroprotection and highlights the importance of proper function of the CXCL12/CXCR4 axis in the CNS.

Rb is able to bind more than 100 different proteins, some of which directly or indirectly control cell fate (Morris and Dyson [@CR22]). These interactions determine the various specific roles of Rb in a cell. Rb mostly acts as a gene suppressor and interacts with well-known transcription factors (e.g., E2F1), as well as enzymes regulating the post-translational modifications of histones (Macaluso et al. [@CR18]). These chromatin modifications favor chromatin condensation, thus inhibiting gene expression by limiting access of transcription complexes to the DNA. Among the Rb-interacting proteins that regulate transcriptional activity, ANP32a/Lanp (also known as pp32, PHAP1, I1PP2A; henceforth referred to as Lanp in this paper) is also found in neurons (Matsuoka et al. [@CR21]; Adegbola and Pasternack [@CR1]). It belongs to a family of leucine-rich repeats-containing proteins (Matilla and Radrizzani [@CR19]). Lanp is an integral component of the inhibitor of histone acetyl transferase complex (INHAT), which blocks transcription by masking N-terminal histone tails from the activity of histone acetyl transferases or through interaction with histone deacetylases (Seo et al. [@CR30]; Seo et al. [@CR31]). Recent studies indicate that, through its INHAT activity, Lanp is involved in both physiological and pathological processes in the CNS (Matilla and Radrizzani [@CR19]). One example is its ability to regulate expression of neurofilament genes in neurons, which affects neuronal differentiation (Kular et al. [@CR16]). Furthermore, alterations of Lanp functions have been implicated in spinocerebellar ataxia type 1 (SCA1) and Alzheimer\'s disease (Matilla et al. [@CR20]; Chen et al. [@CR5]). However, the precise role of Lanp in neuronal survival is still unclear. Furthermore, while its interaction with Rb prevents cell death (Adegbola and Pasternack [@CR1]), studies in proliferating cells indicate that Lanp can also be involved in apoptosis (Jiang et al. [@CR9]; Pan et al. [@CR25]).

Our earlier studies demonstrate that Rb plays a central role in the neuroprotective functions of CXCL12/CXCR4 (Khan et al. [@CR14]). Given the reported interaction of Lanp and Rb in non-neuronal cells (Adegbola and Pasternack [@CR1]), we asked whether they may also interact in neurons supporting their survival. Here, we examined the constitutive and CXCL12-stimulated expression of endogenous Lanp in primary neuronal cultures at different stages of differentiation, its interaction with Rb, and the effect of Lanp overexpression on excitotoxicity. Our data show for the first time a protective role of this nuclear Rb partner in postmitotic neurons.

Materials and methods {#Sec2}
=====================

**Neuronal cultures** Cortical neurons were obtained from the brains of 17-day-old rat fetuses and cultured in a serum-free medium using the bilaminar cell culture system (Banker and Cowan [@CR3]; Kaech and Banker [@CR10]), in which pure neuronal cultures are grown in the presence of a separate glial feeder layer supporting their growth and differentiation. This model reproduces, to a certain extent, the in vivo environment (i.e., the presence of neuronal and non-neuronal cells) and offers the major advantage that neurons can be separated from the glia at any time in order to analyze neuron-specific biological responses. We have extensively used the bilaminar culture system to study expression and function of chemokine receptors in neurons, including CXCR4, and previously demonstrated that the signaling pathways induced by direct activation of neuronal CXCR4 promote neuronal survival mechanisms, even in the absence of glia (Khan et al. [@CR12]; Sengupta et al. [@CR29]). In these studies, unless otherwise noted, CXCL12 treatments (20 nM) were performed in the presence of glia in order to predict the potential outcome of CXCL12 stimulation in vivo. Neurons were always separated from the glia immediately before protein extraction. Cortical neurons were plated on poly-[l]{.smallcaps}-lysine-coated 15-mm coverslips (40 × 10^3^ or 50 × 10^3^ cells) or 60-mm dishes (1 × 10^6^ cells)---depending on the type of experiment. Treatments started after at least 7 days in vitro (7 DIV).

**Immunocytochemistry** Neurons were fixed in 4% paraformaldehyde. For neuronal marker staining, anti-β tubulin III (clone TUJ1, 1:500, from Covance, Berkeley, CA, USA) was used, followed by a cy3-conjugated (Fig. [1](#Fig1){ref-type="fig"}) or a cy2-conjugated secondary antibody (Fig. [5a](#Fig5){ref-type="fig"}). For Lanp staining, anti-Lanp (C-18, 1:200, Santa Cruz Biotechnology, Santa Cruz, CA, USA) was followed by a biotin-conjugated secondary antibody and then by cy3-streptavidin. To visualize FLAG-Lanp-expressing neurons (Fig. [5a](#Fig5){ref-type="fig"}), a DYKDDDDK Tag antibody that detects FLAG (cat\# 2368, 1:800, Cell Signaling Technology, Danvers, MA, USA) was used followed by a cy3-conjugated secondary antibody (Fig. [5a](#Fig5){ref-type="fig"}). Nuclear staining was obtained using Hoechst 33342 (0.5 μl/ml). Cells were observed under an epifluorescent microscope (Olympus IX70, Melville, NY, USA) connected to a CCD camera (Micromax, Trenton, NJ, USA), and images were taken using Metamorph software (Molecular Devices, Sunnyvale, CA, USA). Fig. 1Expression of Lanp in primary cortical neurons: Neurons were cultured for 1--30 days as reported in the methods section, then fixed and stained for endogenous Lanp (*green*) using a specific antibody. The neuronal marker β tubulin III (*red*) was used for visualization of neuronal cell bodies while the nuclei were stained with Hoechst 33342 (*blue*). *Scale bar* = 50 μm

**Western blots** For total cell lysates, neurons were scraped in lysis buffer (25 mM Tris, 150 mM NaCl, 5 mM NaF, 1 mM EDTA, 1 mM DTT, 1% IGEPAL-CA-630, 5 mg each of aprotinin, leupeptin, and pepstatin, 1 mM AEBSF, and 1 mM vanadate), as reported previously (Shimizu et al. [@CR32]; Khan et al. [@CR14]). The protein concentration of cell lysates was determined using the bicinchoninic acid assay from Pierce (Rockford, IL, USA). Equal amounts of proteins (25 μg) were loaded in each lane, separated by SDS-PAGE and transferred to PVDF membranes for immunoblotting. The following primary antibodies were used: anti-Lanp (C-18, 1:1,000; Santa Cruz Biotechnology), anti-Rb (1:4,000,G3-245; BD Biosciences PharMingen, Franklin Lakes, NJ, USA), and anti-Actin (1:5,000, A2066; Sigma-Aldrich, St. Louis, MO, USA). Bands were detected by chemiluminescence using the Pierce SuperSignal West Femto maximum sensitivity kit, according to the manufacturer\'s instructions, and analyzed using the FluorChem 8900 apparatus from Alpha Innotech (San Leandro, CA, USA).

**Immunoprecipitation** For immunoprecipation (IP), 250 μg protein was used for each treatment (Fig. [3](#Fig3){ref-type="fig"}). IP reactions were performed with goat anti-Lanp or monoclonal anti-Rb antibodies and ExactaCruz™ B (sc-45039), or ExactaCruz™ A reagents (sc-45038, Santa Cruz Biotechnology), respectively, were used, according to the manufacturer\'s protocols. The precipitated extracts were immunoblotted and probed for Lanp and Rb proteins as described above.

**Survival assays and transfections** For survival assays, rat cortical neurons (50 × 10^3^ cells per coverslip) were divided in two groups. One group was transfected with pFLAG-Lanp vector (expressing murine Lanp; a gift from Dr. Huda Zoghby, Baylor College of Medicine, Houston, TX, USA), whereas the other group was transfected with a control plasmid expressing GFP; the Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA, USA) was used for transfection (4 μg of plasmid per coverslip). NMDA neurotoxicity assay was conducted as described before (Khan et al. [@CR14]); only the cells expressing GFP and those positive to FLAG immunostaining were counted (Fig. [5](#Fig5){ref-type="fig"}). Transfection efficiency in these experiments was about 35%.

**Materials** Unless otherwise specified, tissue culture media are from Invitrogen. CXCL12 (SDF-1α) was purchased from PeproTech (Rocky Hill, NJ, USA); the chemokine was reconstituted in PBS/0.1% BSA, stored as stock solution at −20°C, and used at a final concentration of 20 nM. AMD3100 was obtained from Sigma-Aldrich, reconstituted in water, and used at final concentrations of 100 ng/ml.

**Statistical analysis** Student\'s *t* test or ANOVA (followed by Newman--Keuls multiple comparison test) were used for statistical analysis (*P* \< 0.05 was considered statistically significant). All data are reported as mean ± SEM. Experiments were performed at least three times.

Results {#Sec3}
=======

**Expression of Lanp protein in cortical neurons and its regulation by the chemokine CXCL12** Recent ex vivo studies have shown that Lanp is expressed predominantly in the neuronal nuclei in distinct regions of the brain (Kovacech et al. [@CR15]). However, earlier studies in neuronal cell lines have suggested the possibility of subcellular translocation (i.e., from nucleus to cytosol) of Lanp upon differentiation (Opal et al. [@CR24]). In order to determine intracellular localization of Lanp in primary neuronal cultures, immunostaining of Lanp was performed on rat cortical neurons cultured for up to 4 weeks (Fig. [1](#Fig1){ref-type="fig"}). At all the time periods studied (from 1 to 30 days), Lanp was found to be expressed mainly in the neuronal nuclei, and no increase in the cytosolic levels of the protein was observed upon neuronal differentiation and maturation at any time (Fig. [1](#Fig1){ref-type="fig"}). Thus, Lanp expression in our primary cultures reflects the in vivo situation; these data also suggest that the expression of the protein in neuronal cell lines may be altered and/or influenced by the cell cycle.Our previous studies indicate that CXCR4 is able to control Rb transcriptional activity (Khan et al. [@CR14]). We have shown that RNAi-mediated Rb depletion in cortical neurons leads to the disruption of CXCR4-mediated protection against neurotoxicity (Khan et al. [@CR14]). Lanp is known to interact with Rb, and this interaction is implicated in the regulation of cell survival in different cell lines (Adegbola and Pasternack [@CR1]). To determine whether the CXCL12/CXCR4 axis can also regulate Lanp protein levels, differentiated rat cortical neurons were treated with CXCL12 (20 nM for 30 min) and protein extracts collected after 3--5 h---in analogy to our studies with Rb. Western blot analysis showed an increase in the endogenous Lanp protein in treated neurons (Fig. [2a](#Fig2){ref-type="fig"}). Pre-treatment with the CXCR4-antagonist, AMD3100 (100 ng/ml, added to the culture medium before CXCL12), abolished the up-regulation of Lanp by CXCR4, confirming the involvement of CXCR4 activity in this effect (Fig. [2a](#Fig2){ref-type="fig"}). Overall, these data indicate that CXCR4 stimulation regulates Lanp in cortical neurons. Fig. 2CXCL12 increases endogenous Lanp levels in cortical neurons: Rat cortical neurons were treated with CXCL12 (20 nM) for 30 min; total cell extracts were collected at 3--5 h after treatment and immunoblotted for Lanp and actin (**a**). Equal amounts of protein (25 μg) were loaded in each lane. Densitometric analysis of three independent experiments is reported in the graph (**A**) as mean±SEM of band density units (*asterisk*, *P* \< 0.05 vs control; *n* = 3). The immunoblots on the bottom (**B**) are from additional studies with neurons treated with the specific CXCR4 antagonist, AMD 3100 (100 ng/ml). AMD was added to the culture 15 min before exposure to CXCL12 (20 nM, 5 h); at the end of the treatment, total cell lysates were extracted and immunoblotted for Lanp and actin. The graph (**B**) represents the densitometric analysis of three independent experiments (*asterisk*, *P* \< 0.05 vs CXCL12)

**Interaction of Lanp with Rb and its involvement in CXCL12 neuroprotection** In order to determine whether Lanp interacts with Rb in neurons, IP studies were performed in cortical neuronal extracts using specific antibodies against Lanp or Rb. Immunoprecipitates were then probed by Western blots for both of these proteins individually (Fig. [3](#Fig3){ref-type="fig"}). These experiments indicate that endogenous Rb and Lanp co-immunoprecipitate, suggesting that they constitutively interact in neurons (Fig. [3](#Fig3){ref-type="fig"}). Next, we asked whether Lanp may be involved in the CXCL12 neuroprotective effect along with Rb; based on our previous studies concerning the regulation of Rb by CXCL12 and its consequences on neuronal survival (Khan et al. [@CR14]), we predicted that CXCL12 would be able to up-regulate Lanp levels in control, as well as NMDA-treated, neurons. To test this hypothesis, neurons were treated with CXCL12 and/or NMDA (100 μM for 20 min) as we previously reported (Khan et al. [@CR14]). Cell extracts were collected after 5 h, immunoblotted, and probed for Lanp. As expected, CXCL12 was able to increase Lanp protein levels in both control and NMDA-treated neurons (Fig. [4](#Fig4){ref-type="fig"}). Fig. 3Endogenous Lanp interacts with Rb in neurons: Equal amounts of neuronal extracts (250 μg; 9DIV) were incubated with either anti-Rb or anti-Lanp before electrophoresis/immunoblotting for both Rb and Lanp. A specific IgG mixture was used as immunoprecipitation controlFig. 4Effect of CXCL12 and NMDA on neuronal Lanp: Vehicle- or CXCL12-treated neurons were stimulated with NMDA (100 μM for 20 min); neuronal extracts were collected after 5 h and immunobotted for Lanp and actin. Densitometric analysis of three independent experiments is reported in the graph as mean±SEM of band density units (*asterisk*, *P* \< 0.05 vs NMDA; *n* = 3)

**Role of Lanp in neuroprotection against NMDA exitotoxicity** To study the role of Lanp in neuronal survival, we used a Lanp expression vector (Fig. [5a](#Fig5){ref-type="fig"}), in which the Lanp sequence is fused with FLAG tag at N-terminal (Matilla et al. [@CR20]). Expression of this vector in primary cortical neurons led to Lanp localization to the nucleus similar to endogenous Lanp (Fig. [5a](#Fig5){ref-type="fig"}). Moreover, Flag--Lanp did not affect cell survival under basal conditions (Fig. [5b](#Fig5){ref-type="fig"}), in contrast to findings in proliferating cells (Jiang et al. [@CR9]; Pan et al. [@CR25]). To explore if Lanp could protect neurons from excitotoxicity, neurons transfected with the same vector were treated with NMDA (100 μM for 20 min) and neuronal death assessed 24 h later; a set of control neurons transfected with a GFP expression vector that underwent the same NMDA treatment was used for comparison. In our previously published studies, this NMDA protocol has shown to induce 60% to 70% neuronal death (Patel et al. [@CR26]). As opposed to NMDA-treated GFP-expressing cells, Lanp-expressing cells were significantly protected from NMDA neurotoxicity (*P* \< 0.001). This is the first evidence of a protective role of Lanp in neurons. Fig. 5Overexpression of Lanp protects neurons from NMDA toxicity: Neurons were transfected with a Flag--Lanp expression vector (pFlagLanp). The exogenous Lanp was visualized by anti-FLAG antibody (**a**). Cells were also stained for a neuronal marker, β tubulin III (*green*) and Hoechst 33342 to visualize nuclei (*blue*). *Scale bar* = 50 μm. Neurons transfected either with control pGFP vector or pLanp vector were treated with NMDA (100 μM, 20 min) and fixed after 24 h to determine cell survival. FLAG--LANP-expressing neurons were visualized by immunocytochemistry and data collected from three independent experiments is expressed as mean±SEM in the graph (**b**). *Asterisk*, *P* vs NMDA (pLanp) \<0.001

Discussion {#Sec4}
==========

This report lends support to the role of CXCL12/CXCR4 axis in the control of neuronal survival and adds Lanp to the list of modulators of gene expression that are regulated by CXCR4. Furthermore, our data suggest that Lanp might be involved in CXCL12/CXCR4 neuroprotection from excitotoxicity (Fig. [6](#Fig6){ref-type="fig"}). Lanp belongs to a family of evolutionarily conserved proteins that have leucine-rich repeats in their N-termini (Matilla and Radrizzani. [@CR19]). These motifs are involved in its interaction with a variety of other proteins, and these interactions determine the range of its functions in a specific cell type. Its acidic C-terminus contains the nuclear localization signal (Pan et al. [@CR25]). Fig. 6A schematic diagram showing the CXCL12/CXCR4-mediated signaling events leading to the putative formation of Lanp-Rb gene repressor complex and its effect on neuronal survival

In this report, we observe that, in primary cortical neurons, native Lanp is expressed predominantly and abundantly in the nucleus throughout neuronal differentiation. Thus, the subcellular translocation of Lanp as shown by an earlier study in a differentiating neuronal cell line seems to be limited to that specific cell line, since all other evidence, including this paper, argues against it being a common mechanism in CNS (Opal et al. [@CR24]; Kovacech et al. [@CR15]). Interestingly, previous studies in proliferating cells have shown that cytosolic Lanp is involved in pathways that affect cell survival. For example, cytosolic Lanp is involved in granzyme A-induced death of cytotoxic T-lymphocyte target cells, or, in other cells, it is a part of a specific complex that promotes formation and function of apoptosome resulting in caspase-mediated cell death (Fan et al. [@CR7]; Jiang et al. [@CR9]; Pan et al. [@CR25]). On the contrary, in postmitotic neurons, Lanp is primarily expressed in the nucleus, can interact with other endogenous nuclear proteins, such as Rb, and promote neuronal survival. Lanp is an essential part of the INHAT complex and, as a result, it is involved in binding to and, thus, masking the N-terminal histone tails from histone acetyl transferase activity (Seo et al. [@CR30]; Seo et al. [@CR31]). Hence, Lanp acts mainly as a gene repressor. Recent studies in neuronal cells indicate that Lanp interacts with a transcriptional repressor, E4F, and enhances its activity, further supporting the nuclear role for Lanp in neurons (Cvetanovic et al. [@CR6]). Moreover, in the context of neurodegenerative disorders, the mutated ataxin-1, which has been implicated in spinocerebellar ataxia type 1 (SCA1), is able to relieve Lanp-E4F gene repression by competing with Lanp for binding to E4F; these interactions might lead to SCA1 neuropatholgy in cerebellum (Cvetanovic et al. [@CR6]). The present study shows that the chemokine CXCL12 positively regulates neuronal Lanp. Considering the interaction of endogenous Lanp with Rb, these data suggest that Lanp might be involved in CXCR4-regulated Rb signaling in neurons. Our previous studies implicate Rb and Rb-mediated gene repression in the neuroprotection action of CXCL12 (Khan et al. [@CR14]). Novel data also show that CXCL12 reduces in vitro/in vivo expression of specific neuronal genes, namely, the NR2B subunit of NMDA receptor, normally controlled by HDAC/Rb-dependent mechanisms (Nicolai et al. [@CR23]; Qiu and Ghosh [@CR28]). As a result of the limited expression of NR2B, CXCL12 would be able to control calcium entry via extrasynaptic NMDA receptor, thus preventing excitotoxicity (Nicolai et al. [@CR23]). The findings reported in the present paper suggest that Lanp might be one of the Rb-interacting proteins involved in neuronal survival in response to NMDA insult.

In agreement with this conclusion, when Lanp is overexpressed in cortical neurons, it retains its nuclear localization and protects neurons against NMDA toxicity. Overall, these results suggest that Lanp acts as an Rb-interacting protein in neurons and may play a significant role in neuronal survival in vivo. These data are in line with other reports showing that Lanp regulates the promoter of the neurofilament light chain (NF-L) gene through inhibition of histone acetylation, and it is thus implicated in neurite outgrowth (Kular et al. [@CR16]). Interestingly, CXCR4 stimulation leads to comparable effects during CNS development and differentiation (Pujol et al. [@CR27]). It is possible that Lanp mediates some of these effects. Unfortunately, we were unable to provide direct evidence about this in the present study as depletion of Lanp in these neurons by shRNA resulted in major alterations of neuronal differentiation, in agreement with and in addition to the previous studies (Kular et al. [@CR16]; Suppl. Figs. [1](#MO7){ref-type=""} and [2](#MO8){ref-type=""}). Thus, NMDA-induced neurotoxicity was negligible in these cultures (not shown). Further investigations using conditional knockout of Lanp or alternative approaches may be necessary to address this issue.

In conclusion, our results show that CXCL12 positively regulates nuclear expression of Lanp, which may act in concert with Rb to ultimately reduce excitotoxicity (Fig. [6](#Fig6){ref-type="fig"}). Although further studies are required to determine the molecular mechanisms involved in the regulation of Lanp by CXCR4 and its direct link to neuroprotection, our data raise the possibility that Lanp, along with Rb, contributes to suppression of specific genes that play a critical role in neuronal survival and differentiation.
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Depletion of Lanp protein by RNAi in primary rat cortical neurons: Neurons were transfected just before plating with an shLanp or a control plasmid (6 μg/10^6^ cells), both expressing green fluorescent protein (GFP), using Amaxa nucleofection. After 9 days in vitro, neurons were collected and processed for Western blot (30 μg protein/lane) as reported in the methods and shown here (*top*); examples of neurons transfected in the same way with shRNA-GFP, immunostained for endogenous Lanp (*red*), and counterstained for nuclear marker using Hoechst 33342 (*blue*) are shown in the bottom micrographs (GIF 53 kb)
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High-resolution image file (TIFF 1047 kb)
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Morphological changes in Lanp-deficient cortical neurons: Neurons were transfected with control or shLanp plasmid (Kular et al. [@CR16]), using Amaxa nucleofection (6 μg/10^6^ cells); both vectors express GFP. These cells were fixed after 9 days of growth in vitro, immunostained for the neuronal marker MAP2 (*red*) and nuclear dye Hoechst 33342 (*blue*). Marked alterations in neurite outgrowth were observed in Lanp-depleted neurons (GIF 190 kb)
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High-resolution image file (TIFF 3825 kb)
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